Gossamer Bio, Inc.
(NASDAQ : GOSS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -0.05%177.430.7%$1339.72m
MRKMerck & Co., Inc. 0.41%91.540.7%$1172.56m
PFEPfizer Inc. -1.61%51.590.9%$1095.84m
LLYEli Lilly & Co. -1.48%319.421.1%$1030.16m
BMYBristol-Myers Squibb Co. -1.23%76.051.0%$995.43m
ABBVAbbVie, Inc. -0.95%151.711.9%$949.65m
AZNAstraZeneca Plc -1.36%65.171.0%$435.47m
SGENSeagen Inc. 1.00%178.705.7%$319.03m
TPTXTurning Point Therapeutics, Inc. -0.12%75.160.0%$287.74m
GSKGSK Plc -0.47%43.330.2%$275.18m
NVSNovartis AG -1.16%83.550.2%$162.66m
HZNPHorizon Therapeutics Plc 0.00%79.765.4%$161.81m
MRTXMirati Therapeutics, Inc. 3.74%69.641.6%$152.19m
ALNYAlnylam Pharmaceuticals, Inc. 1.06%147.398.1%$142.00m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. -0.28%145.310.0%$141.93m

Company Profile

Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi on October 25, 2015 and is headquartered in San Diego, CA.